Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy

BACKGROUND: In a multinational phase 3 trial (VIALE-C), venetoclax plus low-dose cytarabine prolonged overall survival vs placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy, although it was not statistically significant. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamauchi, Takahiro, Yoshida, Chikashi, Usuki, Kensuke, Takada, Satoru, Matsumura, Itaru, Dobashi, Nobuaki, Miyazaki, Yasushi, Miyamoto, Toshihiro, Iida, Hiroatsu, Asou, Norio, Kuroda, Junya, Ichikawa, Satoshi, Komatsu, Norio, Mendes, Wellington, Honda, Hideyuki, Okubo, Sumiko, Kurokawa, Misaki, Jiang, Qi, Wei, Andrew, Ishizawa, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405845/
https://www.ncbi.nlm.nih.gov/pubmed/34322703
http://dx.doi.org/10.1093/jjco/hyab112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405845/
https://www.ncbi.nlm.nih.gov/pubmed/34322703
http://dx.doi.org/10.1093/jjco/hyab112

Ejemplares similares